Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NEXI-002 T Cells |
Synonyms | |
Therapy Description |
NEXI-002 T Cells are T-cells that have been primed to target several multiple myeloma-associated antigens, which may lead to increased killing of tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NEXI-002 T Cells | TAA Primed Antigen-specific CD8+ T Cells NEXI-002|aNEXI 002|NEXI002 | NEXI-002 T Cells are T-cells that have been primed to target several multiple myeloma-associated antigens, which may lead to increased killing of tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04505813 | Phase Ib/II | NEXI-002 T Cells | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Suspended | USA | 0 |